

ASX Announcement

15 August 2024

Successful Surgical Resection of Pancreatic Tumor Following Treatment with OncoSil™ Device in Türkiye

Key Highlights

- ✓ The first patient commercially treated with the OncoSil™ device at Memorial Hospital in Istanbul, Türkiye has undergone a successful resection of the primary tumour.
- ✓ This milestone supports the global expansion of OncoSil™, showcasing its effectiveness in a new international market. OncoSil is actively collaborating with several additional institutions in Türkiye to expand patient access to treatments with the OncoSil™ device.

Sydney, Australia – 15 August 2024: Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** ("**OncoSil**" or "**the Company**") is pleased to announce the successful surgical resection of a pancreatic tumor in the first patient commercially treated with the OncoSil™ device in Türkiye. This significant milestone marks a promising development in the treatment of pancreatic cancer, demonstrating the effectiveness of the OncoSil™ device in combination with chemotherapy.

The patient, who was initially diagnosed with unresectable locally advanced pancreatic cancer, underwent treatment with the OncoSil™ device, combined with chemotherapy. Following this combined treatment approach, the patient's tumor was successfully reduced to a size and state that made it amenable to surgical resection. The surgery was performed by Prof. Dr. Koray Acarli, a renowned specialist in pancreatic surgery.

Prof. Dr. Koray Acarli, the surgeon who performed the resection, shared his perspective on this significant achievement:

"The successful resection following OncoSil™ treatment is a testament to the device's ability to enhance the efficacy of conventional therapies. This breakthrough offers new hope for patients who were previously considered inoperable, and we are excited about the future possibilities this treatment combination holds."

Prof. Dr. Cuneyt Turkmen, a leading Nuclear Medicine physician who administered the OncoSil™ treatment, also expressed his optimism about the future potential of the device:

"The application of the OncoSil™ device in this patient has provided a new avenue for treatment, enabling the reduction of the tumor to a resectable state. This case highlights the potential of OncoSil™ to transform the treatment landscape for patients with locally advanced pancreatic cancer."

OncoSil Medical CEO & Managing Director, Nigel Lange, said: "We are thrilled to see the positive outcome from the first use of the OncoSil™ device in Türkiye. This achievement underscores the global potential of OncoSil™ to improve the lives of patients battling pancreatic cancer. We look forward to advancing our clinical program and bringing this innovative treatment option to more patients worldwide."

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Christian Dal Cin Acclime CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699
--	--	---

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References:

1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics>